Search Results
Your search for this matches 25292 pages
Showing 9801 - 9850Novel Radiopharmaceutical May Aid in Imaging for Patients With Neuroendocrine Tumors and Liver Metastases
For patients with neuroendocrine tumors and liver metastases, a new radiopharmaceutical, Ga-68 DOTA-JR11, has shown a benefit in imaging for tumor detection, staging, and restaging, providing important information to guide treatment. In a head-to-head comparison of two somatostatin receptor (SSTR)...
Study Finds Significant Variation in Hispanic Patients’ Trust of Cancer Information Sources
A study by Camacho-Rivera et al published in Cancer Epidemiology, Biomarkers & Prevention examining how increasing knowledge about cancer and cancer services among Hispanic adults may help in reducing inequities to care has found that there is significant variation by ethnicity and other...
Adding Cyclophosphamide to Bortezomib/Dexamethasone in Patients With Multiple Myeloma and Acute Kidney Injury From Cast Nephropathy
In a French trial reported in the Journal of Clinical Oncology, Bridoux et al found adding cyclophosphamide to bortezomib/dexamethasone offered no benefit for renal recovery of patients with multiple myeloma and initial cast nephropathy not requiring dialysis. Study Details In the multicenter...
FDA Pipeline: Agents for the Treatment of Prostate and Pancreatic Cancers, Marginal Zone Lymphoma
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to relugolix for the treatment of advanced prostate cancer; Fast Track designation to a radioimmunotherapeutic treatment for marginal zone lymphoma; and Orphan Drug designation to a novel monoclonal antibody for...
Personalized RNA-Based Vaccine/Atezolizumab Combination Produced Immune Response in Most Patients With Advanced Tumors
AN APPROACH using an RNA-based personalized cancer vaccine called RO7198457 in combination with the PD-L1 inhibitor atezolizumab has shown a preliminary benefit, according to an early study in patients with advanced solid tumors. The novel combination was well tolerated, and 8% of patients showed a ...
Can Use of an Algorithm Improve the Accuracy and Efficiency of Cervical Cancer Screening?
In a new study published by Wentzensen et al in the Journal of the National Cancer Institute, a computer algorithm improved the accuracy and efficiency of cervical cancer screening compared with cytology (Papanicolaou [Pap] test), the current standard for follow-up of women who test positive in...
Novel Radiopharmaceutical May Aid in Imaging for Patients With Neuroendocrine Tumors and Liver Metastases
For patients with neuroendocrine tumors and liver metastases, a new radiopharmaceutical, Ga-68 DOTA-JR11, has shown a benefit in imaging for tumor detection, staging, and restaging, providing important information to guide treatment. In a head-to-head comparison of two somatostatin receptor (SSTR)...
Study Finds Significant Variation in Hispanic Patients’ Trust of Cancer Information Sources
A study by Camacho-Rivera et al published in Cancer Epidemiology, Biomarkers & Prevention examining how increasing knowledge about cancer and cancer services among Hispanic adults may help in reducing inequities to care has found that there is significant variation by ethnicity and other...
Phase I Trial of Berzosertib Alone or Combined With Carboplatin in Advanced Solid Tumors
In a phase I trial reported in the Journal of Clinical Oncology, Timothy A. Yap, MBBS, PhD, FRCP, and colleagues identified recommended phase II doses of the first-in-class ATR (ataxia telangiectasia and Rad3–related) kinase inhibitor berzosertib alone and in combination with carboplatin and found...
Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
In the phase IIb SADAL trial reported in The Lancet Haematology, Kalakonda et al found that the oral nuclear export inhibitor selinexor produced durable responses in patients with relapsed or refractory diffuse large B-cell lymphoma. Findings in the trial supported the recent accelerated U.S. Food...
Third- or Later-Line Treatment With Infigratinib in Patients With Cholangiocarcinoma and FGR2 Fusions
At the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2020 Virtual, Javle et al reported that third- and later-line treatment with the selective fibroblast growth factor receptor (FGFR) 1–3 inhibitor infigratinib resulted in a progression-free survival and...
Expert Point of View: Toni K. Choueiri, MD
At the Genitourinary Highlights session of the ASCO20 Virtual Scientific Program, Toni K. Choueiri, MD, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, Boston, put these findings into perspective. “This is an important update. The initial publication was with ...
Study Supports Pembrolizumab Plus Axitinib in Previously Untreated Advanced Renal Cell Carcinoma
Extended analysis of the phase III KEYNOTE-426 study upholds pembrolizumab plus axitinib as a preferred front-line regimen over sunitinib in patients with advanced sporadic renal cell carcinoma.1 These updated results were presented at the ASCO20 Virtual Scientific Program by Elizabeth R. Plimack,...
A Visiting Resident Oncologist’s Training During the COVID-19 Pandemic
A visiting away elective is a resident’s designated time to visit another academic program to foster the growth of medical knowledge through patient care from the perspective of another health-care system and educational experience. The time dedicated to make this dream happen is grueling. First is ...
FDA Approves Maintenance Avelumab for the Treatment of Advanced Urothelial Carcinoma
On June 30, the U.S. Food and Drug Administration (FDA) approved avelumab (Bavencio) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy. JAVELIN Bladder 100 Efficacy of avelumab...
PICOS Score May Help Identify Patients With Brain Metastases at Risk of VTE
In a study published by Wolpert et al in the European Journal of Cancer, venous thromboembolic events (VTE) were reported in 12% of a cohort of patients with cancer that had metastasized to the brain. Researchers identified thrombogenicity of primary tumor, immobilization, chemotherapy, obesity,...
Study Finds Racial Disparities in Esophageal Cancer Surgical Rates
A new study published by Savitch et al in the Journal of Gastrointestinal Surgery found that black patients are less likely to receive surgery for resectable esophageal cancer, which may contribute to higher rates of death. “National guidelines suggest that early-stage esophageal cancer should be...
Addition of an ATR Inhibitor to Gemcitabine in Platinum-Resistant High-Grade Serous Ovarian Cancer
As reported in The Lancet Oncology by Panagiotis A. Konstantinopoulos, MD, and colleagues, a phase II trial has shown significantly prolonged progression-free survival with the addition of the ATR (ataxia telangiectasia and Rad3–related) kinase inhibitor berzosertib to gemcitabine in women with...
Meta-analysis of Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer
In a systematic review and meta-analysis of observational studies reported in JAMA Oncology, Nitecki et al found that minimally invasive radical hysterectomy was associated with increased risk of recurrence and all-cause mortality vs open surgery in women with early-stage cervical cancer. Study...
FDA Approves Combination of Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf for HER2-Positive Breast Cancer
On June 29, the U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo) for subcutaneous injection in the following indications: Use in combination with chemotherapy as: Neoadjuvant treatment for patients with...
Expert Point of View: David Wise, MD and Celestia S. “Tia” Higano, MD, FACP
“GnRH antagonists have several advantages over GnRH agonists,” explained David Wise, MD, of Perlmutter Cancer Center at NYU Langone Health in New York. “There is no testosterone flare on initiation [as there is with leuprolide], no increase in cardiac toxicity, and faster onset of action. Currently ...
Novel Androgen-Deprivation Therapy With Relugolix Causes Fewer Cardiac Events Than Leuprolide in Advanced Prostate Cancer
Men with prostate cancer on androgen-deprivation therapy are usually treated with leuprolide, a long-acting injectable luteinizing hormone-releasing hormone (LHRH) agonist requiring an every-3-month injection, but it may be possible for ADT to be delivered by a daily oral treatment, pending...
Biomarker Combination May Help Predict Response to Immunotherapy in Patients With Metastatic Urothelial Carcinoma
In patients with metastatic urothelial carcinoma, a novel combination of biomarkers from baseline tumor tissues was predictive of improved clinical responses and prolonged survival following treatment with immune checkpoint inhibitors, according to findings published by Goswami et al in Science...
COVID-19 Research From the ASCO20 Virtual Scientific Program
With this week bringing record highs of COVID-19 infection across the nation, on The ASCO Post Podcast, we’re revisiting two presentations from the ASCO20 Virtual Scientific Program on the effect of the virus on patients with cancer.
Variant in Gene May Increase Cancer Risk in Those With Common TP53 R337H Mutations
Scientists studying a common TP53 R337H variant found among people of Brazilian descent discovered that a variant in the tumor-suppressor gene XAF1 increases cancer risk when combined with the inherited TP53 R337H mutation. These findings were published by Pinto et al in Science Advances. “We...
Sedentary Behavior and Risk of Cancer Mortality
In a study that investigated objective measures of sedentary behavior and cancer mortality, researchers found that greater inactivity was independently associated with a higher risk of dying from cancer. An accelerometer was used to measure physical activity, rather than relying on participants to...
Leaders of the PROMISE Study Address Racial Inequities in the United States
In 2018, researchers from Dana-Farber Cancer Institute launched a large, ambitious screening study called PROMISE (ClinicalTrials.gov identifier NCT03689595). The objectives of the study were to identify people with premalignant precursor conditions of multiple myeloma, understand the molecular...
Conquer Cancer Honors Early-Career Medical Professionals From Around the World
Conquer Cancer®, the ASCO Foundation honored recipients of the 2020 Medical Student Rotation for Underrepresented Populations (MSR), Resident Travel Awards for Underrepresented Populations (RTA), Long-Term International Fellowship (LIFe), and International Development and Education Awards (IDEA)...
Association of American Cancer Institutes Issues Statement About Racial Discrimination
In further statements from professional oncology organizations about inequities and disparities among racial and ethnic minorities and underserved populations, as well as racism and discrimination, the Association of American Cancer Institutes (AACI) issued the following statement: The AACI...
I’m Not Too Young for Colorectal Cancer
The first symptoms I had of colorectal cancer—blood in my stool and abdominal pain—coincided with surgery I had to remove my appendix in the spring of 2017. My surgeon attributed the symptoms to the appendectomy and to the medications I received both before and after the surgery. In addition to...
AMA Board of Trustees Pledges Action Against Racism and Police Brutality
At a virtual Special Meeting of the American Medical Association (AMA) House of Delegates, the AMA Board of Trustees pledged action to confront systemic racism and police brutality. The AMA released the following statement that was approved at its meeting on June 5, 2020: The AMA recognizes that...
New Information From NCCN on Overcoming Challenges for People With Head and Neck Cancer
The National Comprehensive Cancer Network® (NCCN®) has now published a third book to complete the NCCN Guidelines for Patients®: Head and Neck Cancers series. Each book contains detailed, expert guidance on what to expect and management options for various cancers that impact the mouth and throat....
Melanoma Awareness: Outlook From a Young Adult
When I was 18, I was diagnosed with stage II melanoma. I had a strange spot on my back that I mentioned to my dermatologist, almost as an afterthought. It never occurred to me it could be skin cancer, let alone the most dangerous kind. I have fair skin but was by no means a sun worshipper. My...
Initiate Conversations About Radiation Therapy for Bone Metastases
Although the American Society for Radiation Oncology (ASTRO) has recommended extended-fraction radiation therapy (more than 10 fractions) not be routinely used for palliation of bone metastases,1 a recently published retrospective cohort study using Medicare data for more than 12,000 patients found ...
Extended-Fraction Radiation Therapy for Bone Metastases Represents Low-Value Care but Continues to Be Widely Practiced
An analysis of radiation therapy patterns among more than 12,000 Medicare patients treated for bone metastases found that 23.4% received extended-fraction radiation therapy, “wasting both health-care dollars and precious patient time,” according to the investigators.1 One-third of the treating...
An Honored Poet Explores a Lust for Life on the Boundaries of Near Death
"When the technician leaves the room, I turn my head toward the screen to interpret neoplasms, the webs of nerves, the small lit fonts in which my pathology and/or future or future end might be written. The first tumor I ever saw was a darkness on that screen, round with a long craggy finger...
Integrating Physical Activity Into Cancer Care
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Accumulating evidence suggests the benefits of physical activity through the cancer continuum....
AIDS Research Led to Appreciation of the Power of Plants and Integrative Medicine in Cancer Care for Donald I. Abrams, MD
The path that led Donald I. Abrams, MD, to a career in oncology was a circuitous one. Although his love of science began when he was a student at Cleveland Heights High School in Ohio, and continued during college at Brown University, where he received an AB in molecular biology in 1972, he was...
NCI Renews Comprehensive Cancer Center Designation for Norris Cotton Cancer Center
The National Cancer Institute (NCI) has renewed its Cancer Center Support Grant to Dartmouth and Dartmouth-Hitchcock Norris Cotton Cancer Center (NCCC). The 5-year, $15.5 million grant will provide continued support for NCCC’s clinical care and research missions. NCI recognized the cancer center...
COVID-19 and Patients With Cancer: A Call to Action for Trainees
As oncology trainees, we develop skills to synthesize complex data and communicate this information with empathy as we accompany our patients through the trenches of a cancer diagnosis. With the current COVID-19 pandemic, an unprecedented layer of challenges has surfaced, as our patients who are...
AACR Stands Against Racial Discrimination and Inequality
On June 4, 2020, the American Association for Cancer Research (AACR) released this statement: [AACR] is outraged and saddened about the pervasive racism and social injustices toward African Americans in our country and all people of color around the world. As a scientific organization focused on...
Pigeon English
The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of tolerating cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...
Penn Medicine Announces Appointment of Daniel Yoshor, MD, as Chair, Department of Neurosurgery
Neurosurgeon and neuroscientist Daniel Yoshor, MD, has been named Chair of the Department of Neurosurgery in the Perelman School of Medicine at the University of Pennsylvania and Vice President of Clinical Integration and Innovation for the University of Pennsylvania Health System in Philadelphia. ...
Polio and Cancer Survivor Mickie McGraw Channels the Power of Creative Arts to Heal Broken Bodies and Minds
GUEST EDITOR Dr. Abraham is Professor of Medicine, Lerner College of Medicine, and Chair of the Hematology and Medical Oncology Department at Taussig Cancer Institute, Cleveland Clinic. In this edition of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with pioneering art ...
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
Question 1 Which of the following statements about mixed-cellularity classic Hodgkin lymphoma is correct? A. It has a female predominance. B. This type of classic Hodgkin lymphoma is relatively more common in developing nations and is frequently associated with Epstein-Barr virus (EBV) positivity....
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that occasionally quizzes readers on issues in hematology. In this first-part of a two-part installment, Drs. Abutalib and Medeiros highlight the histologically rare lymphocyte-rich type of classic Hodgkin lymphoma,...
Seattle Cancer Care Alliance Opens New Clinic Dedicated to Gastrointestinal Cancer Care
Seattle Cancer Care Alliance (SCCA) announced the opening of a Gastrointestinal (GI) Care Neighborhood, a new cancer clinic aimed at improving the experience for patients with GI cancers, which features dedicated GI-related cancer care services on one floor of SCCA’s South Lake Union campus. “We...
Study Confirms Effective, Less-Toxic Alternative to Standard Treatment of Adults With Burkitt Lymphoma
In a recent study reported in the Journal of Clinical Oncology,1 an alternative treatment regimen that is less toxic than standard dose-intensive chemotherapy was found to be highly effective for adults with Burkitt lymphoma across all age groups and independent of HIV status. In addition to being...
You-Can-Do-Anything Philosophy Early in Life Inspired Breast Surgeon Laura S. Dominici, MD
Breast surgical oncologist Laura S. Dominici, MD, was born and reared in Litchfield, a small town in the southern portion of New Hampshire. “Our house was on a long dirt road, in a very rural area,” she shared. “There were only about 5,000 residents in the town. My mother was a teacher, and my dad...
Expert Point of View: Komal Jhaveri, MD, FACP
Komal Jhaveri, MD, FACP, Attending Physician at Memorial Sloan Kettering Cancer Center, Clinical Director of the Early Drug Development Service, and Assistant Professor of Medicine at Weill Cornell Medical College, served as the study’s invited discussant. Dr. Jhaveri noted that, in SOLAR-1, the...
